Smartleaf Asset Management
TLX icon

Smartleaf Asset Management’s Telix Pharmaceuticals TLX Stock Holding History

Smartleaf Asset Management’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418 Hold
37
– – ﹤0.01% 3226
2026
Q1 		$332 Sell
37
-35
-49% -$267 ﹤0.01% 3283
2025
Q4 		$558 Buy
+72
New +$693 ﹤0.01% 3251

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Integrated Wealth Concepts
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Smartleaf Asset Management's TLX Position: Q2 2026 in Review

Smartleaf Asset Management held its Telix Pharmaceuticals (TLX) position steady in Q2 2026 at 37 shares worth $418. The position accounts for ﹤0.01% of the portfolio, ranked #3226.

Smartleaf Asset Management first reported a position in TLX in Q4 2025 and has held it in 3 quarters since. The position peaked at $558 in Q4 2025. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Smartleaf Asset Management held 37 shares of Telix Pharmaceuticals worth $418 as of Q2 2026.
  • Smartleaf Asset Management left its Telix Pharmaceuticals share count unchanged in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #3226 holding.
  • Smartleaf Asset Management first reported a position in Telix Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Smartleaf Asset Management's Telix Pharmaceuticals position peaked at $558 in Q4 2025.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.